Clinical trials: Vincristine, open to volunteers
Low Grade Astrocytoma, Low Grade Glioma
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that…
- Conditions
- Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
- Trial name
- NCT04166409
- Testing
- Biospecimen Collection, Carboplatin, Echocardiography Test
- Where
- 132 sites in United States, Canada and 1 more
- Volunteers
- 170 people
- Sponsor
- National Cancer Institute (NCI)
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Retinoblastoma
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients: Study 1, a randomized phase-II study evaluating the…
- Trial name
- RETINO 2018 (NCT04681417)
- Testing
- Melphalan or Melphalan + Topotecan, etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy, Carboplatin administered on Day 1
- Where
- 28 sites in France
- Volunteers
- 225 people
- Sponsor
- Institut Curie
Ewing's Sarcoma
A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
This study is a randomized, controlled, multicenter, prospective clinical trial with a planned enrollment of 74 patients, who will be randomly assigned in a 2:1 ratio.
- Trial name
- NCT07092306
- Testing
- Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT), Irinotecan Combined with Temozolomide and Vincristine (VIT)
- Volunteers
- 74 people
- Sponsor
- Tang Xiaodong
Wilms Tumor
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles…
- Trial name
- MetroWilms (NCT05384821)
- Testing
- Vincristine, Irinotecan, Temozolomide
- Where
- 18 sites in France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
DLBCL - Diffuse Large B Cell Lymphoma, TP53
AZA Combined With RCHOP in P53-mutated DLBCL.
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
- Trial name
- NCT06158399
- Testing
- Azacitidine in combination with R-CHOP
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) among adult patients, therapeutic outcomes remain suboptimal despite advances in chemotherapy and immunotherapy.
- Trial name
- NCT06387121
- Testing
- Vincristine, Cyclophosphamide, Dexamethasone
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Leukemia of Ambiguous Lineage
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
In this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled.
- Trial name
- NCT04440267
- Testing
- vincristine, daunorubicin, cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Retinoblastoma
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
- Trial name
- NCT05080010
- Testing
- 3 cycles chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
To evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
- Trial name
- NCT07744737
- Testing
- Pirtobrutinib plus R-CHOP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Changzhou No.2 People's Hospital
Follicular Lymphoma
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory…
- Trial name
- NCT06911502
- Testing
- Golcadomide, Rituximab, Lenalidomide
- Where
- 160 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- Celgene
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or…
- Trial name
- NCT06249191
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
T-cell Lymphoblastic Lymphoma
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%~85%.
- Trial name
- NCT05681260
- Testing
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Children's Cancer Group, China
Osteosarcoma, Ewing Sarcoma
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care.
- Trial name
- NCT07321912
- Testing
- Eflornithine, Topotecan, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 406 people
- Sponsor
- Milton S. Hershey Medical Center
Hepatoblastoma
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
A Phase 3 multi-institutional study for treatment of children with newly diagnosed hepatoblastoma using a modified Paediatric Hepatic International Tumour Trial (PHITT) strategy incorporating a randomized assessment of sodium…
- Trial name
- NCT04478292
- Testing
- Sodium Thiosulfate Injection, Primary surgery resection, mono CDDP-Group A2
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Shanghai Children's Medical Center
Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+…
- Trial name
- NCT06846463
- Testing
- Zanubrutinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Virginia Commonwealth University
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the…
- Conditions
- Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
- Trial name
- CCCG-I/HR-ALL (NCT06764238)
- Testing
- Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B)
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 1,800 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent
Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Relapsed/refractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries.
- Conditions
- Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL
- Trial name
- NCT07039877
- Testing
- Venetoclax low dose with itraconazole
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Ewing Sarcoma, Myelosuppression
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
This study is a prospective, open label, randomized controlled clinical trial aimed at patients with Ewing's sarcoma who have not received systematic anti-tumor treatment in the past.
- Trial name
- NCT06699472
- Testing
- Chemotherapy, Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group of extranidal T-cell lymphomas characterized by skin involvement. Current treatment options for CTCL are limited.
- Conditions
- Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome, Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT07535710
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine